These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 29401320

  • 1. Abdominal submuscular implant of subcutaneous implantable cardioverter-defibrillator in a young child.
    Kwok SY, Yam N, Lun KS, Chen RH, Au TW, Yung TC.
    Europace; 2018 Sep 01; 20(FI2):f248. PubMed ID: 29401320
    [No Abstract] [Full Text] [Related]

  • 2. Recent developments in the subcutaneous ICD.
    Willcox ME, Prutkin JM, Bardy GH.
    Trends Cardiovasc Med; 2016 Aug 01; 26(6):526-35. PubMed ID: 27079889
    [Abstract] [Full Text] [Related]

  • 3. Application of the main implantable cardioverter-defibrillator trials and the 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
    Proclemer A, Ghidina M.
    J Cardiovasc Med (Hagerstown); 2007 May 01; 8(5):320-3. PubMed ID: 17443096
    [No Abstract] [Full Text] [Related]

  • 4. Relationship of Shock Energy to Impedance During Subcutaneous Implantable Cardioverter-Defibrillator Testing.
    Payne JE, Badertscher P, Field ME, Sturdivant JL, Gold MR.
    Circ Arrhythm Electrophysiol; 2020 Sep 01; 13(9):e008631. PubMed ID: 32703008
    [No Abstract] [Full Text] [Related]

  • 5. Antitachycardia pacing therapy for the successful treatment of lead fracture.
    Bhimani AA, Deeprasertkul P, Nannapaneni N, Carayannopoulos GN.
    J Cardiovasc Electrophysiol; 2015 Feb 01; 26(2):228-9. PubMed ID: 25354719
    [No Abstract] [Full Text] [Related]

  • 6. The US Experience of the Wearable Cardioverter-Defibrillator in Pediatric Patients.
    Spar DS, Bianco NR, Knilans TK, Czosek RJ, Anderson JB.
    Circ Arrhythm Electrophysiol; 2018 Jul 01; 11(7):e006163. PubMed ID: 29945928
    [Abstract] [Full Text] [Related]

  • 7. Clinical impact of defibrillation testing at the time of implantable cardioverter-defibrillator insertion.
    Hadid C, Atienza F, Strasberg B, Arenal Á, Codner P, González-Torrecilla E, Datino T, Percal T, Almendral J, Ortiz M, Martins R, Martinez-Alzamora N, Fernandez Aviles F.
    Cardiol J; 2015 Jul 01; 22(3):253-9. PubMed ID: 25179316
    [Abstract] [Full Text] [Related]

  • 8. Should catheter ablation be the preferred therapy for reducing ICD shocks?: Ventricular tachycardia in patients with an implantable defibrillator warrants catheter ablation.
    Kuck KH.
    Circ Arrhythm Electrophysiol; 2009 Dec 01; 2(6):713-20; discussion 720. PubMed ID: 20009082
    [No Abstract] [Full Text] [Related]

  • 9. Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in TMEM43 Following Implantable Cardioverter Defibrillator Therapy.
    Hodgkinson KA, Howes AJ, Boland P, Shen XS, Stuckless S, Young TL, Curtis F, Collier A, Parfrey PS, Connors SP.
    Circ Arrhythm Electrophysiol; 2016 Mar 01; 9(3):. PubMed ID: 26966288
    [Abstract] [Full Text] [Related]

  • 10. Combining shock reduction strategies to enhance ICD therapy: a role for computer modeling.
    Volosin KJ, Exner DV, Wathen MS, Sherfesee L, Scinicariello AP, Gillberg JM.
    J Cardiovasc Electrophysiol; 2011 Mar 01; 22(3):280-9. PubMed ID: 20958831
    [Abstract] [Full Text] [Related]

  • 11. Primary prevention of sudden cardiac death: one step forwards and one step backwards.
    Cain ME.
    Nat Clin Pract Cardiovasc Med; 2006 Mar 01; 3(3):115. PubMed ID: 16505838
    [No Abstract] [Full Text] [Related]

  • 12. Long-Term Outcome in High-Risk Patients With Hypertrophic Cardiomyopathy After Primary Prevention Defibrillator Implants.
    Rowin EJ, Burrows A, Madias C, Estes NAM, Link MS, Maron MS, Maron BJ.
    Circ Arrhythm Electrophysiol; 2020 Oct 01; 13(10):e008123. PubMed ID: 32897759
    [Abstract] [Full Text] [Related]

  • 13. Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy.
    Francia P, Adduci C, Palano F, Semprini L, Serdoz A, Montesanti D, Santini D, Musumeci B, Salvati A, Volpe M, Autore C.
    J Cardiovasc Electrophysiol; 2015 Aug 01; 26(8):893-899. PubMed ID: 25996259
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
    Buber J, Luria D, Gurevitz O, Bar-Lev D, Eldar M, Glikson M.
    Europace; 2014 Feb 01; 16(2):227-34. PubMed ID: 24108231
    [Abstract] [Full Text] [Related]

  • 15. New approach to implantable cardioverter-defibrillators in small pediatric patients: dorsal positioning of superior vena cava shock lead in a 3-year-old.
    Pedersen SB, Smerup MH, Nielsen JC.
    J Thorac Cardiovasc Surg; 2014 Jul 01; 148(1):358-60. PubMed ID: 24685380
    [No Abstract] [Full Text] [Related]

  • 16. Reprogramming the tachycardia parameters with long-detection strategy in patients with pre-existing implantable cardioverter-defibrillator.
    Bozyel S, Aktas M, Mutluer FO, Guler TE, Dervis E, Argan O, Celikyurt U, Agir A, Vural A.
    Acta Cardiol; 2019 Jun 01; 74(3):246-251. PubMed ID: 30058473
    [Abstract] [Full Text] [Related]

  • 17. Inappropriate implantable cardioverter-defibrillator therapy: many causes and many possible solutions.
    Zareba W.
    Cardiol J; 2009 Jun 01; 16(5):391-3. PubMed ID: 19753515
    [No Abstract] [Full Text] [Related]

  • 18. Repetitive shock therapy of subcutaneous implantable cardioverter defibrillators in a patient with idiopathic ventricular fibrillation: What is the mechanism?
    Hasegawa K, Miyazaki S, Ishikawa E, Mukai M, Aoyama D, Nodera M, Kaseno K, Tada H.
    J Cardiovasc Electrophysiol; 2019 Oct 01; 30(10):2121-2124. PubMed ID: 31332856
    [No Abstract] [Full Text] [Related]

  • 19. Implantable Cardioverter-Defibrillators and Wearable Defibrillators: Guidelines and Updates.
    Mathuria N.
    Tex Heart Inst J; 2020 Feb 01; 47(1):51-52. PubMed ID: 32148457
    [No Abstract] [Full Text] [Related]

  • 20. Wearable cardioverter-defibrillator as a bridge to implantable cardioverter-defibrillator treatment.
    Technol Eval Cent Assess Program Exec Summ; 2010 Nov 01; 25(2):1-5. PubMed ID: 21638938
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.